Launches:
July 26, 2017
Amgen has entrusted us with the representation of two new licences: Neupogen (filgrastim) and Neulastim (pegfilgrastim).
We are proud to continue expanding our portfolio, commiting ourselves to improving the quality of life for patients, with more treatment opportunities
